Report Detail
Global Long-acting Beta Agonists Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4742357 |
- 28 September, 2026 |
- Global |
- 103 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Long-acting Beta Agonists market size was valued at US$ 4940 million in 2025 and is forecast to a readjusted size of US$ 6113 million by 2032 with a CAGR of 3.1% during review period.
Long-Acting Beta Agonists (LABAs) are inhaled medications that are used in the treatment of asthma and chronic obstuctive pulmonary disease (COPD).
The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products.
This report is a detailed and comprehensive analysis for global Long-acting Beta Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-acting Beta Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Long-acting Beta Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Long-acting Beta Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Long-acting Beta Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-acting Beta Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-acting Beta Agonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis, Teva, Organon, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Long-acting Beta Agonists market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Serevent
Foradil
Striverdi
Other
Market segment by Application
COPD
Asthma
Other
Major players covered
GSK
AstraZeneca
Chiesi
Boehringer Ingelheim
Novartis
Teva
Organon
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-acting Beta Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting Beta Agonists, with price, sales quantity, revenue, and global market share of Long-acting Beta Agonists from 2021 to 2026.
Chapter 3, the Long-acting Beta Agonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting Beta Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Long-acting Beta Agonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting Beta Agonists.
Chapter 14 and 15, to describe Long-acting Beta Agonists sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Long-acting Beta Agonists Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Serevent
- 1.3.3 Foradil
- 1.3.4 Striverdi
- 1.3.5 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Long-acting Beta Agonists Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 COPD
- 1.4.3 Asthma
- 1.4.4 Other
- 1.5 Global Long-acting Beta Agonists Market Size & Forecast
- 1.5.1 Global Long-acting Beta Agonists Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Long-acting Beta Agonists Sales Quantity (2021-2032)
- 1.5.3 Global Long-acting Beta Agonists Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 GSK
- 2.1.1 GSK Details
- 2.1.2 GSK Major Business
- 2.1.3 GSK Long-acting Beta Agonists Product and Services
- 2.1.4 GSK Long-acting Beta Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 GSK Recent Developments/Updates
- 2.2 AstraZeneca
- 2.2.1 AstraZeneca Details
- 2.2.2 AstraZeneca Major Business
- 2.2.3 AstraZeneca Long-acting Beta Agonists Product and Services
- 2.2.4 AstraZeneca Long-acting Beta Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 AstraZeneca Recent Developments/Updates
- 2.3 Chiesi
- 2.3.1 Chiesi Details
- 2.3.2 Chiesi Major Business
- 2.3.3 Chiesi Long-acting Beta Agonists Product and Services
- 2.3.4 Chiesi Long-acting Beta Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Chiesi Recent Developments/Updates
- 2.4 Boehringer Ingelheim
- 2.4.1 Boehringer Ingelheim Details
- 2.4.2 Boehringer Ingelheim Major Business
- 2.4.3 Boehringer Ingelheim Long-acting Beta Agonists Product and Services
- 2.4.4 Boehringer Ingelheim Long-acting Beta Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Boehringer Ingelheim Recent Developments/Updates
- 2.5 Novartis
- 2.5.1 Novartis Details
- 2.5.2 Novartis Major Business
- 2.5.3 Novartis Long-acting Beta Agonists Product and Services
- 2.5.4 Novartis Long-acting Beta Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Novartis Recent Developments/Updates
- 2.6 Teva
- 2.6.1 Teva Details
- 2.6.2 Teva Major Business
- 2.6.3 Teva Long-acting Beta Agonists Product and Services
- 2.6.4 Teva Long-acting Beta Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Teva Recent Developments/Updates
- 2.7 Organon
- 2.7.1 Organon Details
- 2.7.2 Organon Major Business
- 2.7.3 Organon Long-acting Beta Agonists Product and Services
- 2.7.4 Organon Long-acting Beta Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Organon Recent Developments/Updates
3 Competitive Environment: Long-acting Beta Agonists by Manufacturer
- 3.1 Global Long-acting Beta Agonists Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Long-acting Beta Agonists Revenue by Manufacturer (2021-2026)
- 3.3 Global Long-acting Beta Agonists Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Long-acting Beta Agonists by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Long-acting Beta Agonists Manufacturer Market Share in 2025
- 3.4.3 Top 6 Long-acting Beta Agonists Manufacturer Market Share in 2025
- 3.5 Long-acting Beta Agonists Market: Overall Company Footprint Analysis
- 3.5.1 Long-acting Beta Agonists Market: Region Footprint
- 3.5.2 Long-acting Beta Agonists Market: Company Product Type Footprint
- 3.5.3 Long-acting Beta Agonists Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Long-acting Beta Agonists Market Size by Region
- 4.1.1 Global Long-acting Beta Agonists Sales Quantity by Region (2021-2032)
- 4.1.2 Global Long-acting Beta Agonists Consumption Value by Region (2021-2032)
- 4.1.3 Global Long-acting Beta Agonists Average Price by Region (2021-2032)
- 4.2 North America Long-acting Beta Agonists Consumption Value (2021-2032)
- 4.3 Europe Long-acting Beta Agonists Consumption Value (2021-2032)
- 4.4 Asia-Pacific Long-acting Beta Agonists Consumption Value (2021-2032)
- 4.5 South America Long-acting Beta Agonists Consumption Value (2021-2032)
- 4.6 Middle East & Africa Long-acting Beta Agonists Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Long-acting Beta Agonists Sales Quantity by Type (2021-2032)
- 5.2 Global Long-acting Beta Agonists Consumption Value by Type (2021-2032)
- 5.3 Global Long-acting Beta Agonists Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Long-acting Beta Agonists Sales Quantity by Application (2021-2032)
- 6.2 Global Long-acting Beta Agonists Consumption Value by Application (2021-2032)
- 6.3 Global Long-acting Beta Agonists Average Price by Application (2021-2032)
7 North America
- 7.1 North America Long-acting Beta Agonists Sales Quantity by Type (2021-2032)
- 7.2 North America Long-acting Beta Agonists Sales Quantity by Application (2021-2032)
- 7.3 North America Long-acting Beta Agonists Market Size by Country
- 7.3.1 North America Long-acting Beta Agonists Sales Quantity by Country (2021-2032)
- 7.3.2 North America Long-acting Beta Agonists Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Long-acting Beta Agonists Sales Quantity by Type (2021-2032)
- 8.2 Europe Long-acting Beta Agonists Sales Quantity by Application (2021-2032)
- 8.3 Europe Long-acting Beta Agonists Market Size by Country
- 8.3.1 Europe Long-acting Beta Agonists Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Long-acting Beta Agonists Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Long-acting Beta Agonists Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Long-acting Beta Agonists Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Long-acting Beta Agonists Market Size by Region
- 9.3.1 Asia-Pacific Long-acting Beta Agonists Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Long-acting Beta Agonists Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Long-acting Beta Agonists Sales Quantity by Type (2021-2032)
- 10.2 South America Long-acting Beta Agonists Sales Quantity by Application (2021-2032)
- 10.3 South America Long-acting Beta Agonists Market Size by Country
- 10.3.1 South America Long-acting Beta Agonists Sales Quantity by Country (2021-2032)
- 10.3.2 South America Long-acting Beta Agonists Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Long-acting Beta Agonists Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Long-acting Beta Agonists Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Long-acting Beta Agonists Market Size by Country
- 11.3.1 Middle East & Africa Long-acting Beta Agonists Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Long-acting Beta Agonists Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Long-acting Beta Agonists Market Drivers
- 12.2 Long-acting Beta Agonists Market Restraints
- 12.3 Long-acting Beta Agonists Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Long-acting Beta Agonists and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Long-acting Beta Agonists
- 13.3 Long-acting Beta Agonists Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Long-acting Beta Agonists Typical Distributors
- 14.3 Long-acting Beta Agonists Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Long-acting Beta Agonists. Industry analysis & Market Report on Long-acting Beta Agonists is a syndicated market report, published as Global Long-acting Beta Agonists Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Long-acting Beta Agonists market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
